Literature DB >> 24597548

Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors.

Nidhi Singh1, Manisha Yadav, Abhishek Kumar Singh, Harish Kumar, Shailendra Kumar Dhar Dwivedi, Jay Sharan Mishra, Anagha Gurjar, Amit Manhas, Sharat Chandra, Prem Narayan Yadav, Kumaravelu Jagavelu, Mohammad Imran Siddiqi, Arun Kumar Trivedi, Naibedya Chattopadhyay, Sabyasachi Sanyal.   

Abstract

The synthetic nuclear bile acid receptor (farnesoid X receptor [FXR]) agonist GW4064 is extensively used as a specific pharmacological tool to illustrate FXR functions. We noticed that GW4064 activated empty luciferase reporters in FXR-deficient HEK-293T cells. We postulated that this activity of GW4064 might be routed through as yet unknown cellular targets and undertook an unbiased exploratory approach to identify these targets. Investigations revealed that GW4064 activated cAMP and nuclear factor for activated T-cell response elements (CRE and NFAT-RE, respectively) present on these empty reporters. Whereas GW4064-induced NFAT-RE activation involved rapid intracellular Ca(2+) accumulation and NFAT nuclear translocation, CRE activation involved soluble adenylyl cyclase-dependent cAMP accumulation and Ca(2+)-calcineurin-dependent nuclear translocation of transducers of regulated CRE-binding protein 2. Use of dominant negative heterotrimeric G-protein minigenes revealed that GW4064 caused activation of Gαi/o and Gq/11 G proteins. Sequential pharmacological inhibitor-based screening and radioligand-binding studies revealed that GW4064 interacted with multiple G protein-coupled receptors. Functional studies demonstrated that GW4064 robustly activated H1 and H4 and inhibited H2 histamine receptor signaling events. We also found that MCF-7 breast cancer cells, reported to undergo GW4064-induced apoptosis in an FXR-dependent manner, did not express FXR, and the GW4064-mediated apoptosis, also apparent in HEK-293T cells, could be blocked by selective histamine receptor regulators. Taken together, our results demonstrate identification of histamine receptors as alternate targets for GW4064, which not only necessitates cautious interpretation of the biological functions attributed to FXR using GW4064 as a pharmacological tool but also provides a basis for the rational designing of new pharmacophores for histamine receptor modulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24597548      PMCID: PMC5414852          DOI: 10.1210/me.2013-1353

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  76 in total

1.  Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.

Authors:  G Powis; M J Seewald; C Gratas; D Melder; J Riebow; E J Modest
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

2.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules.

Authors:  Michael H A Roehrl; Sunghyun Kang; José Aramburu; Gerhard Wagner; Anjana Rao; Patrick G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-06       Impact factor: 11.205

3.  The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization.

Authors:  Kenneth C Hess; Brian H Jones; Becky Marquez; Yanqiu Chen; Teri S Ord; Margarita Kamenetsky; Catarina Miyamoto; Jonathan H Zippin; Gregory S Kopf; Susan S Suarez; Lonny R Levin; Carmen J Williams; Jochen Buck; Stuart B Moss
Journal:  Dev Cell       Date:  2005-08       Impact factor: 12.270

4.  Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.

Authors:  Liwei Chen; Shen-Shu Sung; M L Richard Yip; Harshani R Lawrence; Yuan Ren; Wayne C Guida; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Mol Pharmacol       Date:  2006-05-22       Impact factor: 4.436

Review 5.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

Authors:  Anna C Calkin; Peter Tontonoz
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-14       Impact factor: 94.444

6.  Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor.

Authors:  Darcey L H Smith; Pavitra Keshavan; Uri Avissar; Kashif Ahmed; Stephen D Zucker
Journal:  Carcinogenesis       Date:  2010-03-01       Impact factor: 4.944

Review 7.  Histamine and histamine receptor antagonists in cancer biology.

Authors:  Bruno Blaya; Francesca Nicolau-Galmés; Shawkat M Jangi; Idoia Ortega-Martínez; Erika Alonso-Tejerina; Juan Burgos-Bretones; Gorka Pérez-Yarza; Aintzane Asumendi; María D Boyano
Journal:  Inflamm Allergy Drug Targets       Date:  2010-07

8.  Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.

Authors:  Jenny Kaeding; Emmanuel Bouchaert; Julie Bélanger; Patrick Caron; Sarah Chouinard; Mélanie Verreault; Olivier Larouche; Georges Pelletier; Bart Staels; Alain Bélanger; Olivier Barbier
Journal:  Biochem J       Date:  2008-03-01       Impact factor: 3.857

9.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

10.  TORCs: transducers of regulated CREB activity.

Authors:  Michael D Conkright; Gianluca Canettieri; Robert Screaton; Ernesto Guzman; Loren Miraglia; John B Hogenesch; Marc Montminy
Journal:  Mol Cell       Date:  2003-08       Impact factor: 17.970

View more
  8 in total

1.  Intracellular calcium signaling regulates autophagy via calcineurin-mediated TFEB dephosphorylation.

Authors:  Yanju Tong; Fuyong Song
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

2.  The M. tuberculosis HAD phosphatase (Rv3042c) interacts with host proteins and is inhibited by Clofazimine.

Authors:  Sonal Shree; Abhishek Kumar Singh; Richa Saxena; Harish Kumar; Aparna Agarwal; Vijay Kumar Sharma; Kanchan Srivastava; Kishore Kumar Srivastava; Sabyasachi Sanyal; Ravishankar Ramachandran
Journal:  Cell Mol Life Sci       Date:  2016-03-17       Impact factor: 9.261

3.  Nonacidic Chemotype Possessing N-Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists.

Authors:  Naoki Teno; Yukiko Yamashita; Yusuke Iguchi; Ko Fujimori; Mizuho Une; Tomoko Nishimaki-Mogami; Takie Hiramoto; Keigo Gohda
Journal:  ACS Med Chem Lett       Date:  2018-01-04       Impact factor: 4.345

4.  Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer.

Authors:  Karthic Chandran; Sudeshna Goswami; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2016-03-29

5.  Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches.

Authors:  Meimei Chen; Xuemei Yang; Xinmei Lai; Jie Kang; Huijuan Gan; Yuxing Gao
Journal:  Int J Mol Sci       Date:  2016-04-08       Impact factor: 5.923

6.  Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.

Authors:  L Absil; F Journé; D Larsimont; J J Body; L Tafforeau; D Nonclercq
Journal:  BMC Cancer       Date:  2020-07-10       Impact factor: 4.430

7.  Optical control of the nuclear bile acid receptor FXR with a photohormone.

Authors:  Johannes Morstein; Julie B Trads; Konstantin Hinnah; Sabine Willems; David M Barber; Michael Trauner; Daniel Merk; Dirk Trauner
Journal:  Chem Sci       Date:  2019-11-19       Impact factor: 9.825

Review 8.  A Recent Ten-Year Perspective: Bile Acid Metabolism and Signaling.

Authors:  Yulia Shulpekova; Elena Shirokova; Maria Zharkova; Pyotr Tkachenko; Igor Tikhonov; Alexander Stepanov; Alexandra Sinitsyna; Alexander Izotov; Tatyana Butkova; Nadezhda Shulpekova; Vladimir Nechaev; Igor Damulin; Alexey Okhlobystin; Vladimir Ivashkin
Journal:  Molecules       Date:  2022-03-18       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.